Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

Fig. 3

Characterization of the tumor microenvironment. A Representative images of multiplex immunofluorescent staining for the indicated markers. B Quantification of immunofluorescence images for indicated markers as scored by number of cells per mm2 in either the tumor or stroma in patients treated with monotherapy or combination therapy. C Quantification of stromal tumor-infiltrating lymphocytes as determined by a comprehensive algorithm that was established for cell segmentation and cell phenotyping for cell counts with double positivity in tumor and stroma regions, respectively, subsequently calculated the density of these population. D TILs was scored on the H&E stained slides as the proportion of the tumor-stroma interface area occupied by mononuclear inflammatory cells [23]. E HLA was scored as the estimated relative expression of HLA-ABC positive tumor cells in the chromogenic HLA IHC-stained slides

Back to article page